Compare · NSPR vs RMD
NSPR vs RMD
Side-by-side comparison of InspireMD Inc. (NSPR) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NSPR and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $30.74B, about 1518.0x NSPR ($20.3M).
- Over the past year, NSPR is down 71.8% and RMD is down 25.4% - RMD leads by 46.4 points.
- RMD has been more active in the news (4 items in the past 4 weeks vs 3 for NSPR).
- RMD has more recent analyst coverage (25 ratings vs 1 for NSPR).
- Company
- InspireMD Inc.
- ResMed Inc.
- Price
- $0.72+0.00%
- $212.07-5.08%
- Market cap
- $20.3M
- $30.74B
- 1M return
- +0.70%
- +1.75%
- 1Y return
- -71.82%
- -25.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 3
- 4
- Recent ratings
- 1
- 25
InspireMD Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NSPR
- InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
- InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- InspireMD Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- InspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
- InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
- InspireMD Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Stuka Paul bought $17,500 worth of shares (20,000 units at $0.88), increasing direct ownership by 3% to 667,871 units (SEC Form 4)
- InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest RMD
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.